Pulmonary marginal zone lymphoma

A single centre experience and review of the SEER database

Alexandra Stefanovic, Daniel Morgensztern, Thomas Fong, Izidore Lossos

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database. Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution. Initial management included observation (n = 4), surgery (n = 5), combination chemotherapy (n = 7), single-agent rituximab (n = 3) and radioimmunotherapy (n = 2). Complete remission was observed in 10, partial remission in 3, stable disease in 7, and disease progression in 1 patient. With a median follow-up of 20 months, Kaplan-Meier estimates for progression-free and overall survival (OS) at 80 months were 90% and 95%, respectively. We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database. Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease. After a median follow-up of 35 months, median OS was 112 months, and disease-specific median survival was not reached. At 90 months, disease-specific survival was 85% (CI 77-92) with no significant differences in outcome between patients presenting with different stages. Our single institution experience and review of the SEER database, confirm the indolent features and favourable outcome of this rare disease.

Original languageEnglish
Pages (from-to)1311-1320
Number of pages10
JournalLeukemia and Lymphoma
Volume49
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Lymphoma
Epidemiology
Databases
Lung
Lymphoid Tissue
Rare Diseases
Survival
Radioimmunotherapy
Kaplan-Meier Estimate
Combination Drug Therapy
Natural History
Disease-Free Survival
Disease Progression
Observation
Biopsy
Therapeutics

Keywords

  • BALT lymphoma
  • Extranodal lymphoma
  • Lung
  • MALT lymphoma
  • Marginal zone lymphoma
  • Non-Hodgkin lymphoma
  • Pulmonary lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pulmonary marginal zone lymphoma : A single centre experience and review of the SEER database. / Stefanovic, Alexandra; Morgensztern, Daniel; Fong, Thomas; Lossos, Izidore.

In: Leukemia and Lymphoma, Vol. 49, No. 7, 01.07.2008, p. 1311-1320.

Research output: Contribution to journalArticle

Stefanovic, Alexandra ; Morgensztern, Daniel ; Fong, Thomas ; Lossos, Izidore. / Pulmonary marginal zone lymphoma : A single centre experience and review of the SEER database. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 7. pp. 1311-1320.
@article{7d8418f7ee204080baf641acd1992574,
title = "Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database",
abstract = "Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database. Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution. Initial management included observation (n = 4), surgery (n = 5), combination chemotherapy (n = 7), single-agent rituximab (n = 3) and radioimmunotherapy (n = 2). Complete remission was observed in 10, partial remission in 3, stable disease in 7, and disease progression in 1 patient. With a median follow-up of 20 months, Kaplan-Meier estimates for progression-free and overall survival (OS) at 80 months were 90{\%} and 95{\%}, respectively. We identified 326 patients (59{\%} females and 41{\%} males; median age 68 [30 to 85) with BALT lymphoma in the SEER database. Fifty-five per cent had stage IE, 10{\%} stage IIE, 3{\%} stage IIIE, and 22{\%} stage IV disease. After a median follow-up of 35 months, median OS was 112 months, and disease-specific median survival was not reached. At 90 months, disease-specific survival was 85{\%} (CI 77-92) with no significant differences in outcome between patients presenting with different stages. Our single institution experience and review of the SEER database, confirm the indolent features and favourable outcome of this rare disease.",
keywords = "BALT lymphoma, Extranodal lymphoma, Lung, MALT lymphoma, Marginal zone lymphoma, Non-Hodgkin lymphoma, Pulmonary lymphoma",
author = "Alexandra Stefanovic and Daniel Morgensztern and Thomas Fong and Izidore Lossos",
year = "2008",
month = "7",
day = "1",
doi = "10.1080/10428190802064933",
language = "English",
volume = "49",
pages = "1311--1320",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Pulmonary marginal zone lymphoma

T2 - A single centre experience and review of the SEER database

AU - Stefanovic, Alexandra

AU - Morgensztern, Daniel

AU - Fong, Thomas

AU - Lossos, Izidore

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database. Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution. Initial management included observation (n = 4), surgery (n = 5), combination chemotherapy (n = 7), single-agent rituximab (n = 3) and radioimmunotherapy (n = 2). Complete remission was observed in 10, partial remission in 3, stable disease in 7, and disease progression in 1 patient. With a median follow-up of 20 months, Kaplan-Meier estimates for progression-free and overall survival (OS) at 80 months were 90% and 95%, respectively. We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database. Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease. After a median follow-up of 35 months, median OS was 112 months, and disease-specific median survival was not reached. At 90 months, disease-specific survival was 85% (CI 77-92) with no significant differences in outcome between patients presenting with different stages. Our single institution experience and review of the SEER database, confirm the indolent features and favourable outcome of this rare disease.

AB - Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database. Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution. Initial management included observation (n = 4), surgery (n = 5), combination chemotherapy (n = 7), single-agent rituximab (n = 3) and radioimmunotherapy (n = 2). Complete remission was observed in 10, partial remission in 3, stable disease in 7, and disease progression in 1 patient. With a median follow-up of 20 months, Kaplan-Meier estimates for progression-free and overall survival (OS) at 80 months were 90% and 95%, respectively. We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database. Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease. After a median follow-up of 35 months, median OS was 112 months, and disease-specific median survival was not reached. At 90 months, disease-specific survival was 85% (CI 77-92) with no significant differences in outcome between patients presenting with different stages. Our single institution experience and review of the SEER database, confirm the indolent features and favourable outcome of this rare disease.

KW - BALT lymphoma

KW - Extranodal lymphoma

KW - Lung

KW - MALT lymphoma

KW - Marginal zone lymphoma

KW - Non-Hodgkin lymphoma

KW - Pulmonary lymphoma

UR - http://www.scopus.com/inward/record.url?scp=47649119630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649119630&partnerID=8YFLogxK

U2 - 10.1080/10428190802064933

DO - 10.1080/10428190802064933

M3 - Article

VL - 49

SP - 1311

EP - 1320

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -